Developer docs
API playgroundTry for free, no card

Search company profiles

Revalia Bio

Full company profile

uuid00002dn

Namestring
Revalia Bio
Legal namestring
Revalia Bio, Inc.
Websiteurl
revaliabio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Revalia Bio is a private, venture-backed pre-clinical research company founded in 2022 by Yale scientists Greg Tietjen, Jenna DiRito, and Kourosh Saeb-Parsy, headquartered in New Haven, Connecticut. The company operates a five-layer 'Human Data Stack' platform that transforms donated human organs and tissues (sourced through partnerships with organ procurement organizations) into multi-modal biological datasets, then applies Revalia AI — a foundational model layer — to generate decision-ready insights for drug and device development. Predictive outputs cover safety signals, dose selection, target selection, patient selection, PK/PD profiles, biodistribution, mechanism of action, and optimized delivery. The company's 2025 launch of a purpose-built Organ ICU facility in New Haven and integration of Draper's PREDICT96 microphysiological system operationalize this pipeline at scale.

Revalia Bio serves pharmaceutical and biotechnology companies as primary customers, with regulatory bodies and healthcare providers identified as secondary segments. The go-to-market is enterprise field sales with a consultation-based, 'Book a Call' engagement model and quote-based pricing rather than self-serve or marketplace distribution. Revenue is generated through professional services (human organ research projects) and what the company describes as subscription/recurring AI-powered drug development insights, though specific pricing is not publicly disclosed. The company reports two signed top pharmaceutical customers and first revenue from human organ research services in 2023.

Capital structure is private with no subsidiaries or parent entities. Equity funding totals approximately $19.5 million across an initial 2023 round ($5M from Connecticut Innovations, Leva Capital, Overmatch Ventures) and a 2024-2025 seed round ($14.5M led by America's Frontier Fund and Sierra Ventures, with National Kidney Foundation and Connecticut Innovations). In December 2025, the company was awarded up to $26.7 million under the ARPA-H CATALYST program, in partnership with Draper, the Krishnaswamy Lab at Yale, and LifeShare Network, to develop in silico models of human physiology. The board includes America's Frontier Fund's Brian Wilcove, deep-tech investor Ben Yu, former Fed Vice Chair and TIAA CEO Roger Ferguson, and Pamir Ventures' Milad Alucozai.

Short descriptiontext

Revalia Bio operates a five-layer 'Human Data Stack' platform that uses donated human organs and AI to deliver predictive pre-clinical drug safety and efficacy insights for pharmaceutical and biotechnology clients. Founded in 2022 by Yale scientists and headquartered in New Haven, Connecticut.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew Haven, United States
HQ citystring
New Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical drug testing, organ-on-chip technology, human biology research, drug safety prediction, AI drug development
Industry2 codes
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Preclinical Drug Development Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Human Organ Research Services
TypeProfessional Services
Description

Revenue generated from providing human organ research services to pharmaceutical and biotech companies. The company provides early predictive insights for drug development through human data trials.

news.crunchbase.com
2AI-Powered Drug Development Insights
TypeSubscription Recurring
Description

Providing decision-ready insights for drug and device development based on human biology data, potentially through subscriptions or project-based engagements.

revaliabio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Revalia Bio transforms donated human organs and tissues into high-fidelity biological data using its AI-powered Human Data Stack, delivering 'Human Data Trials' as an alternative to traditional preclinical animal testing. The five-layer platform (Generate, Ingest, Integrate, Interpret, Deliver) and Revalia AI engine produce decision-ready insights across drug safety, dose selection, target selection, patient selection, PK/PD profiles, biodistribution, mechanism of action, and optimized delivery for pharmaceutical and biotechnology customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Superior prediction of drug-induced liver injury compared to animal models
Product overview1 text field

Revalia Bio operates as a platform company offering the Human Data Stack, an end-to-end infrastructure consisting of five integrated layers (Generate, Ingest, Integrate, Interpret, and Deliver). The platform transforms donated human organs and tissues into high-fidelity biological data through its proprietary Revalia AI engine and state-of-the-art Organ ICU facility. The core Human Data Trials offering provides early predictive insights for drug development, including safety signals, dose selection, target selection, patient selection, PK/PD profiles, biodistribution profiles, mechanism of action, and optimized delivery predictions. Founded by Yale scientists in 2022, the company has developed partnerships with pharmaceutical companies and is funded through ARPA-H contracts.

Product and service3 records
1Human Data Stack
CategoryPlatform
Description

End-to-end five-layer infrastructure (Generate, Ingest, Integrate, Interpret, Deliver) that converts donated human organs and tissues into multi-modal biological datasets for drug and device development, with AI embedded at every junction.

2Revalia AI
CategoryAI/Analytics Engine
Description

Foundational AI/ML engine powering the Human Data Stack, delivering decision-ready insights across drug development including Safety Signals, Dose Selection, Target Selection, Patient Selection, PK/PD Profiles, Biodistribution Profiles, Mechanism of Action, and Optimized Delivery.

3Human Data Trials
CategoryPreclinical Research Service
Description

New category of preclinical testing that uses donated human organs and tissues to provide early, predictive insights for drug development, serving pharmaceutical and biotech customers as an alternative to animal testing and traditional preclinical models.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-27
Description

Draper leads the CATALYST program awarded up to $26.7 million in ARPA-H funding. The partnership develops in silico models of human physiology using a four-layer Human Data Stack integrating patient records, donated organ data, tissue biopsies, and Draper's PREDICT96 microphysiological system to predict drug safety and effectiveness.

2Krishnaswamy Lab at Yale University
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-27
Description

Yale research lab awarded ARPA-H funding as a key partner in the CATALYST program. The Krishnaswamy Lab contributes computational models using AI and machine learning to develop the Human Data Stack for drug development.

medicine.yale.edu
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-27
Description

Partner in the CATALYST program contributing to the development of in silico models of human physiology for drug development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with leading organ procurement organizations to source donated human organs and tissues for research while ensuring ethical handling and respect for donor gifts.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with healthcare partners to ensure every donor gift is handled with highest ethical standards, transparency, and respect throughout its lifecycle.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Recursion combines high-throughput wet-lab biology with AI/ML to drive drug discovery at scale; it competes with Revalia for the same AI-enabled preclinical narrative at large pharma, though with a broader target-discovery franchise.

TypeDirect peer
Description

TissUse develops multi-organ-chip platforms that connect several human organ equivalents on a single chip, directly overlapping with Revalia's multi-organ, microphysiological system strategy for systemic drug safety/efficacy testing.

TypeDirect peer
Description

Emulate is the leading commercial organ-on-chip company whose Organ-Chip platform is the most direct competitor to Revalia's organ-based preclinical offering; both target pharma customers seeking human-relevant preclinical alternatives to animal models.

TypeDirect peer
Description

Mimetas provides OrganoPlate-based organ-on-chip and disease modeling platforms used by pharma for preclinical testing, positioning it as a direct competitor in the human-relevant in vitro preclinical space.

TypeBroad incumbent
Description

Schrödinger operates a physics-based computational platform for drug discovery and materials, competing for preclinical R&D budgets at large pharma and offering overlapping predictive-modeling capabilities to Revalia AI.

6CN Bio
TypeDirect peer
Description

CN Bio offers single- and multi-organ microphysiological systems (including PhysioMimix) for drug development, directly competing with Revalia's organ-on-chip + PREDICT96 microphysiological approach for pharma preclinical customers.

TypeBroad incumbent
Description

Insilico Medicine is a more established AI-driven drug discovery platform using generative AI and multi-omics; it competes with Revalia AI for pharma R&D share but is broader in scope and later-stage across target ID through preclinical pipelines.

TypeDirect peer
Description

InSilicoTrials runs in silico clinical and preclinical trials using computational models, competing for the same 'replace/supplement animal testing' pharma budget as Revalia's Human Data Trials offering, albeit via simulation rather than donated organs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Revalia Bio

Preclinical Drug Development Servicesrevaliabio.com

Revalia Bio operates a five-layer 'Human Data Stack' platform that uses donated human organs and AI to deliver predictive pre-clinical drug safety and efficacy insights for pharmaceutical and biotechnology clients. Founded in 2022 by Yale scientists and headquartered in New Haven, Connecticut.

What Revalia Bio does

Revalia Bio is a private, venture-backed pre-clinical research company founded in 2022 by Yale scientists Greg Tietjen, Jenna DiRito, and Kourosh Saeb-Parsy, headquartered in New Haven, Connecticut. The company operates a five-layer 'Human Data Stack' platform that transforms donated human organs and tissues (sourced through partnerships with organ procurement organizations) into multi-modal biological datasets, then applies Revalia AI — a foundational model layer — to generate decision-ready insights for drug and device development. Predictive outputs cover safety signals, dose selection, target selection, patient selection, PK/PD profiles, biodistribution, mechanism of action, and optimized delivery. The company's 2025 launch of a purpose-built Organ ICU facility in New Haven and integration of Draper's PREDICT96 microphysiological system operationalize this pipeline at scale.

Revalia Bio serves pharmaceutical and biotechnology companies as primary customers, with regulatory bodies and healthcare providers identified as secondary segments. The go-to-market is enterprise field sales with a consultation-based, 'Book a Call' engagement model and quote-based pricing rather than self-serve or marketplace distribution. Revenue is generated through professional services (human organ research projects) and what the company describes as subscription/recurring AI-powered drug development insights, though specific pricing is not publicly disclosed. The company reports two signed top pharmaceutical customers and first revenue from human organ research services in 2023.

Capital structure is private with no subsidiaries or parent entities. Equity funding totals approximately $19.5 million across an initial 2023 round ($5M from Connecticut Innovations, Leva Capital, Overmatch Ventures) and a 2024-2025 seed round ($14.5M led by America's Frontier Fund and Sierra Ventures, with National Kidney Foundation and Connecticut Innovations). In December 2025, the company was awarded up to $26.7 million under the ARPA-H CATALYST program, in partnership with Draper, the Krishnaswamy Lab at Yale, and LifeShare Network, to develop in silico models of human physiology. The board includes America's Frontier Fund's Brian Wilcove, deep-tech investor Ben Yu, former Fed Vice Chair and TIAA CEO Roger Ferguson, and Pamir Ventures' Milad Alucozai.

Revalia Bio firmographics

Firmographics
Name
Revalia Bio
Legal name
Revalia Bio, Inc.
Website
https://revaliabio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Revalia Bio operates a five-layer 'Human Data Stack' platform that uses donated human organs and AI to deliver predictive pre-clinical drug safety and efficacy insights for pharmaceutical and biotechnology clients. Founded in 2022 by Yale scientists and headquartered in New Haven, Connecticut.
Ownership category
akta.pro rank

Revalia Bio industry classification

Industry
Product category
Preclinical Drug Development Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Preclinical drug testing
  • Organ-on-chip technology
  • Human biology research
  • Drug safety prediction
  • AI drug development

Where Revalia Bio is headquartered

Location

Headquarters

HQ city
New Haven
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Revalia Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Human Organ Research Services: Revenue generated from providing human organ research services to pharmaceutical and biotech companies. The company provides early predictive insights for drug development through human data trials.
  2. AI-Powered Drug Development Insights: Providing decision-ready insights for drug and device development based on human biology data, potentially through subscriptions or project-based engagements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Revalia Bio product offering

Product offering

Core offering

Revalia Bio transforms donated human organs and tissues into high-fidelity biological data using its AI-powered Human Data Stack, delivering 'Human Data Trials' as an alternative to traditional preclinical animal testing. The five-layer platform (Generate, Ingest, Integrate, Interpret, Deliver) and Revalia AI engine produce decision-ready insights across drug safety, dose selection, target selection, patient selection, PK/PD profiles, biodistribution, mechanism of action, and optimized delivery for pharmaceutical and biotechnology customers.

Product overview

Revalia Bio operates as a platform company offering the Human Data Stack, an end-to-end infrastructure consisting of five integrated layers (Generate, Ingest, Integrate, Interpret, and Deliver). The platform transforms donated human organs and tissues into high-fidelity biological data through its proprietary Revalia AI engine and state-of-the-art Organ ICU facility. The core Human Data Trials offering provides early predictive insights for drug development, including safety signals, dose selection, target selection, patient selection, PK/PD profiles, biodistribution profiles, mechanism of action, and optimized delivery predictions. Founded by Yale scientists in 2022, the company has developed partnerships with pharmaceutical companies and is funded through ARPA-H contracts.

Differentiator

Problem solved

Functional benefit

Products and services

  • Human Data Stack End-to-end five-layer infrastructure (Generate, Ingest, Integrate, Interpret, Deliver) that converts donated human organs and tissues into multi-modal biological datasets for drug and device development, with AI embedded at every junction.
  • Revalia AI Foundational AI/ML engine powering the Human Data Stack, delivering decision-ready insights across drug development including Safety Signals, Dose Selection, Target Selection, Patient Selection, PK/PD Profiles, Biodistribution Profiles, Mechanism of Action, and Optimized Delivery.
  • Human Data Trials New category of preclinical testing that uses donated human organs and tissues to provide early, predictive insights for drug development, serving pharmaceutical and biotech customers as an alternative to animal testing and traditional preclinical models.

Quantifiable outcome

  • Superior prediction of drug-induced liver injury compared to animal models

Companies that use Revalia Bio

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Revalia Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Revalia Bio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship and core.

  • DraperflagshipStrategic or Co-development Partner · 27 February 2026Draper leads the CATALYST program awarded up to $26.7 million in ARPA-H funding. The partnership develops in silico models of human physiology using a four-layer Human Data Stack integrating patient records, donated organ data, tissue biopsies, and Draper's PREDICT96 microphysiological system to predict drug safety and effectiveness.
  • Krishnaswamy Lab at Yale UniversityflagshipStrategic or Co-development Partner · 27 February 2026Yale research lab awarded ARPA-H funding as a key partner in the CATALYST program. The Krishnaswamy Lab contributes computational models using AI and machine learning to develop the Human Data Stack for drug development.
  • LifeShare NetworkflagshipStrategic or Co-development Partner · 27 February 2026Partner in the CATALYST program contributing to the development of in silico models of human physiology for drug development.
  • Organ Procurement Organizations (OPOs)coreStrategic or Co-development PartnerPartnership with leading organ procurement organizations to source donated human organs and tissues for research while ensuring ethical handling and respect for donor gifts.
  • Healthcare InstitutionscoreStrategic or Co-development PartnerPartnership with healthcare partners to ensure every donor gift is handled with highest ethical standards, transparency, and respect throughout its lifecycle.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Revalia Bio competitors and assessment

Company assessment

Broad incumbents

  • Recursion: Recursion combines high-throughput wet-lab biology with AI/ML to drive drug discovery at scale; it competes with Revalia for the same AI-enabled preclinical narrative at large pharma, though with a broader target-discovery franchise.
  • Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery and materials, competing for preclinical R&D budgets at large pharma and offering overlapping predictive-modeling capabilities to Revalia AI.
  • Insilico Medicine: Insilico Medicine is a more established AI-driven drug discovery platform using generative AI and multi-omics; it competes with Revalia AI for pharma R&D share but is broader in scope and later-stage across target ID through preclinical pipelines.

Direct peers

  • TissUse: TissUse develops multi-organ-chip platforms that connect several human organ equivalents on a single chip, directly overlapping with Revalia's multi-organ, microphysiological system strategy for systemic drug safety/efficacy testing.
  • Emulate: Emulate is the leading commercial organ-on-chip company whose Organ-Chip platform is the most direct competitor to Revalia's organ-based preclinical offering; both target pharma customers seeking human-relevant preclinical alternatives to animal models.
  • Mimetas: Mimetas provides OrganoPlate-based organ-on-chip and disease modeling platforms used by pharma for preclinical testing, positioning it as a direct competitor in the human-relevant in vitro preclinical space.
  • CN Bio: CN Bio offers single- and multi-organ microphysiological systems (including PhysioMimix) for drug development, directly competing with Revalia's organ-on-chip + PREDICT96 microphysiological approach for pharma preclinical customers.
  • InSilicoTrials: InSilicoTrials runs in silico clinical and preclinical trials using computational models, competing for the same 'replace/supplement animal testing' pharma budget as Revalia's Human Data Trials offering, albeit via simulation rather than donated organs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revalia Bio social profiles

Digital presence

Revalia Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Revalia Bio leadership team

Management profile

Number of profiles

Profiles13 records

Revalia Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Revalia Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revalia Bio

What does Revalia Bio do?

Revalia Bio transforms donated human organs and tissues into high-fidelity biological data using its AI-powered Human Data Stack, delivering 'Human Data Trials' as an alternative to traditional preclinical animal testing. The five-layer platform (Generate, Ingest, Integrate, Interpret, Deliver) and Revalia AI engine produce decision-ready insights across drug safety, dose selection, target selection, patient selection, PK/PD profiles, biodistribution, mechanism of action, and optimized delivery for pharmaceutical and biotechnology customers.

Is Revalia Bio a public or private company?

Revalia Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Revalia Bio founded?

Revalia Bio was founded in 2022. It employs 11 to 50 people.

Where is Revalia Bio based?

Revalia Bio is headquartered in New Haven, United States, in the North America region.

How does Revalia Bio make money?

Two revenue lines are on record. Human Organ Research Services are the primary driver. The others are AI-Powered Drug Development Insights.

Who are Revalia Bio's main competitors?

Broad incumbents on record are Recursion, Schrödinger and Insilico Medicine. Direct peers are TissUse, Emulate, Mimetas, CN Bio and InSilicoTrials.

Does Revalia Bio have an API?

No public API is recorded for Revalia Bio.

What industry is Revalia Bio in?

Revalia Bio's product category is Preclinical Drug Development Services. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip), with a secondary code of HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling. Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceRevalia Bio Taps Former Lilly and Verily Exec to Lead Next Growth PhaseRevalia Bio appointed Casimir Starsiak III as President and CEO and Greg Tietjen as Chief Innovation Officer. Starsiak will lead commercial expansion and partnerships, while Tietjen will drive integration of research and technology. The company is entering its next growth phase with additional resources.Hartford Business JournalYale bioscience spinout Revalia Bio names Eli Lilly exec CEORevalia Bio named Eli Lilly executive Casimir Starsiak as president and CEO, effective Sept. 1. He will lead commercial expansion and pharmaceutical partnerships, while co-founder Greg Tietjen becomes chief innovation officer. The company uses perfusion technology to study drugs in human organs.MedCity NewsOrgan-on-a-chip, Organoids, but Drug Testing on Whole Organs? This Startup is Betting On ItThe FDA announced a new proposed guidance in late May to reduce unnecessary animal testing for cancer drugs, representing a major regulatory shift toward New Approach Methodologies (NAMs) in drug development. Three startups—Revalia Bio, Vivodyne, and Emulate—are highlighted for their different approaches to human-based drug testing, including whole-organ perfusion, lab-grown tissue models, and organ-on-a-chip systems. Revalia Bio recently won a $26.7 million ARPA-H contract to build AI-driven digital twin models, while Vivodyne has raised $40 million in Series A funding and Emulate has announced collaborations with AstraZeneca, Roche, Takeda, Merck, and Janssen.YaleNewsKrishnaswamy lab is key partner in team awarded ARPA-H funding to revolutionize drug developmentThe Krishnaswamy Lab at Yale School of Medicine has been awarded up to $26.7 million in funding from the Advanced Research Projects Agency for Health (ARPA-H) as a key partner in the Draper-led CATALYST program, which aims to revolutionize drug development through computational models of human physiology. The team, which also includes Revalia Bio, Inc. and LifeShare Network, will develop AI and machine learning models using a multi-layered "Human Data Stack" combining patient data, organ data, cellular data, and microphysiological data to predict drug safety and effectiveness. The research will initially focus on the human liver and kidney to address drug-induced toxicity, with findings expected to expand to other organ systems.BioSpaceRevalia Bio Awarded Up To $26.7 Million ARPA-H Contract Award to Advance Drug Development with Human Data TrialsRevalia Bio has been awarded up to a $26.7 million contract under ARPA-H's CATALYST program to develop AI-driven models for drug safety using human data from donor organs, aiming to reduce animal testing and accelerate drug development. The project involves building advanced in silico models trained on multimodal human datasets, including organ-on-chip platforms, to better predict drug behavior in humans.PharmiWeb.comRevalia Bio Awarded Up To $26.7 Million ARPA-H Contract Award to Advance Drug Development with Human Data TrialsRevalia Bio announced it will serve as technical lead for an up to $26.7 million contract awarded under the ARPA-H CATALYST program, aimed at advancing drug safety and efficacy prediction using human data trials. The project will build AI-driven models trained on donated human organs, organ-on-chip platforms, and multimodal datasets to reduce reliance on animal testing and cut costly late-stage drug failures. Revalia will collaborate with a national consortium including research institutions and a top-10 pharma company to accelerate the development of safer therapies.Tely10 Companies Delivering Publication-Grade Insights for Biopharma TeamsThe article profiles ten companies, including Revalia Bio, Atropos Health, and Merck, that are providing AI-driven and human-data-based insights to accelerate biopharma drug development. A key highlight is the strategic partnership between Merck and Atropos Health, which leverages AI to generate real-world evidence for regulatory submissions in under 48 hours. These innovations aim to reduce reliance on animal models and improve clinical trial efficiency through precise, publication-grade data.VentureRadarNew Funding Rounds in in vitro diagnosticsThe article lists multiple venture capital funding rounds for various biotech and diagnostics startups, including Byome Labs raising €3.6M, Revalia Bio securing $14.5M, and Mirxes obtaining $40M in structured financing. These companies are developing technologies ranging from AI-driven skincare diagnostics to portable pathogen identification and RNA-based cancer detection. The report serves as a roundup of recent equity investments in the in vitro diagnostics and life sciences sectors.